Lipid phenotypes in patients with nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 65, Issue 9, 2016, Pages 1391-1398

  Du, Tingting ^a   Sun, Xingxing ^a   Yuan, Gang ^a   Zhou, Xinrong ^a   Lu, Huimin ^b   Lin, Xuan ^b   Yu, Xuefeng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN IRON AND STEEL GROUP CORPORATION   (China)

Author keywords

Association; Lipid phenotype; Nonalcoholic fatty liver disease

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; CHINESE; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT ANALYSIS; LIPID METABOLISM; METABOLISM; MIDDLE AGED; NORMAL HUMAN;

ADULT; AGED; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE;

EID: 84978933372     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.06.006     Document Type: Article

References (38)

1. [1] Browning, JD, Szczepaniak, LS, Dobbins, R, Nuremberg, P, Horton, JD, Cohen, JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:6 (2004), 1387–1395.
2. [2] Chalasani, N, Younossi, Z, Lavine, JE, Diehl, AM, Brunt, EM, Cusi, K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:7 (2012), 1592–1609.
3. [3] Vernon, G, Baranova, A, Younossi, ZM, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:3 (2011), 274–285.
4. [4] Kim, D, Choi, SY, Park, EH, Lee, W, Kang, JH, Kim, W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56:2 (2012), 605–613.
5. [5] Al Rifai, M, Silverman, MG, Nasir, K, Budoff, MJ, Blankstein, R, Szklo, M, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 239:2 (2015), 629–633.
6. [6] Mellinger, JL, Pencina, KM, Massaro, JM, Hoffmann, U, Seshadri, S, Fox, CS, et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham heart study. J Hepatol 63:2 (2015), 470–476.
7. [7] Stepanova, M, Younossi, ZM, Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10:6 (2012), 646–650.
8. [8] Targher, G, Day, CP, Bonora, E, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:14 (2010), 1341–1350.
9. [9] Adams, LA, Lymp, JF, St Sauver, J, Sanderson, SO, Lindor, KD, Feldstein, A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:1 (2005), 113–121.
10. [10] Yusuf, S, Hawken, S, Ounpuu, S, Dans, T, Avezum, A, Lanas, F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 364:9438 (2004), 937–952.
11. [11] Speliotes, EK, Massaro, JM, Hoffmann, U, Vasan, RS, Meigs, JB, Sahani, DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology 51:6 (2010), 1979–1987.
12. [12] Mari, M, Caballero, F, Colell, A, Morales, A, Caballeria, J, Fernandez, A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4:3 (2006), 185–198.
13. [13] Van Rooyen, DM, Larter, CZ, Haigh, WG, Yeh, MM, Ioannou, G, Kuver, R, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141:4 (2011), 1393–1403 [403 e1–5].
14. [14] Paramsothy, P, Knopp, RH, Bertoni, AG, Blumenthal, RS, Wasserman, BA, Tsai, MY, et al. Association of combinations of lipid parameters with carotid intima–media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 56:13 (2010), 1034–1041.
15. [15] Du, T, Yu, X, Yuan, G, Zhang, J, Sun, X, Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk. Cardiovasc Diabetol, 14, 2015, 144.
16. [16] American Diabetes Association, (2) Classification and diagnosis of diabetes. Diabetes Care(38 Suppl.), 2015, S8–S16.
17. [17] Mittelstaedt, CA, Vincent, LM, Abdominal ultrasound: Churchill Livingstone. 1987.
18. [18] Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285(19), 2001, 97–2486.
19. [19] Neuschwander-Tetri, BA, Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52:2 (2010), 774–788.
20. [20] Lahdenpera, S, Syvanne, M, Kahri, J, Taskinen, MR, Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39:4 (1996), 453–461.
21. [21] Toledo, FG, Sniderman, AD, Kelley, DE, Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29:8 (2006), 1845–1850.
22. [22] Sniderman, AD, Scantlebury, T, Cianflone, K, Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:6 (2001), 447–459.
23. [23] Sniderman, A, Couture, P, de Graaf, J, Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 6:6 (2010), 335–346.
24. [24] Rashid, S, Watanabe, T, Sakaue, T, Lewis, GF, Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:6 (2003), 421–429.
25. [25] Athyros, VG, Tziomalos, K, Gossios, TD, Griva, T, Anagnostis, P, Kargiotis, K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis. Lancet 376:9756 (2010), 1916–1922.
26. [26] Tziomalos, K, Athyros, VG, Paschos, P, Karagiannis, A, Nonalcoholic fatty liver disease and statins. Metabolism 64:10 (2015), 1215–1223.
27. [27] Katsiki, N, Mikhailidis, DP, Mantzoros, CS, Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism, 2016 [Epub ahead of print].
28. [28] Takeshita, Y, Takamura, T, Honda, M, Kita, Y, Zen, Y, Kato, K, et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57:5 (2014), 878–890.
29. [29] Grundy, SM, Cleeman, JI, Merz, CN, Brewer, HB Jr., Clark, LT, Hunninghake, DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44:3 (2004), 720–732.
30. [30] Amarenco, P, Labreuche, J, Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:5 (2009), 453–463.
31. [31] Barter, P, Gotto, AM, LaRosa, JC, Maroni, J, Szarek, M, Grundy, SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:13 (2007), 1301–1310.
32. [32] Kolovou, GD, Mikhailidis, DP, Kovar, J, Lairon, D, Nordestgaard, BG, Ooi, TC, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9:3 (2011), 258–270.
33. [33] Musso, G, Gambino, R, De Michieli, F, Cassader, M, Rizzetto, M, Durazzo, M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:4 (2003), 909–916.
34. [34] Cassader, M, Gambino, R, Musso, G, Depetris, N, Mecca, F, Cavallo-Perin, P, et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 36:10 (2001), 1117–1124.
35. [35] Mota, M, Banini, BA, SC, C, Sanyal, AJ, Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism, 2016 [Epub ahead of print].
36. [36] Musso, G, Gambino, R, Durazzo, M, Biroli, G, Carello, M, Faga, E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42:5 (2005), 1175–1183.
37. [37] Zhang, T, Zhang, C, Zhang, Y, Tang, F, Li, H, Zhang, Q, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis 240:1 (2015), 144–148.
38. [38] Sirota, JC, McFann, K, Targher, G, Johnson, RJ, Chonchol, M, Jalal, DI, Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and nutrition examination survey. Metabolism 62:3 (2013), 392–399.